|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Depression - Novel Drugs to Grow Third-line Market
Datamonitor, March 2007, Pages: 206
We believe that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options.
GSK’s gepirone ER is likely to be the first pipeline drug to enter the market and exploit this opportunity, with forecast sales of $615m in 2016.
Scope of this title:
Analysis of patient potential, unmet needs and clinical trial design in depression, overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the market
Detailed profiles of key compounds in development for use in depression, with forecasts of drug revenues to 2016
Discussion of GSK’s and Sanofi-Aventis’ strategies, and insight from key industry opinion leaders
Highlights of this title:
Of the novel pipeline drugs in late-stage development for depression, we believe gepirone ER has the most revenue potential over the forecast period. This will be the first pipeline drug to enter the market and compete for market share with current third-line therapies, and has the considerable marketing support of GSK. Wyeth’s lifecycle management strategy of developing the Effexor reformulation Pristiq, will not successfully maintain revenues for its depression franchise following generic incursion of Effexor XR in 2010. Agomelatine, a melatonin agonist and serotonin receptor ligand, will be a valuable treatment option for mild/moderate MDD patients with prominent sleep disorder co-morbidity or an add-on therapy for more severe MDD sufferers.
Reasons to order your copy:
Understand unmet needs in the depression market based on key opinion leader comments
Benchmark key late-stage depression compounds against current market leaders
Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
Customers who bought this item also bought
Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market
Pipeline Insight: Depression - Novel therapies key to market penetration
CNS Drug Discoveries: Depression Chapter
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
Drugs of Tomorrow 2001: Depression - A Future Away From Serotonin?
Inhalers Clinical Trial Analysis
Neurostimulation Devices Clinical Trial Analysis
Collagens Clinical Trial Analysis
Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline
Thought Leader Insight & Analysis: Anxiety & Depression
Drug Eluting Stent (DES) Clinical Trial Analysis
Deep Brain Stimulators Clinical Trial Analysis
|
|
|
|
